This is a randomized, double-blind, placebo controlled, single and multiple ascending dose study in healthy participants.
This first in human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and food effect of GBT021601, a hemoglobin S (HbS) polymerization inhibitor, in healthy participants.